LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

Search

Schrodinger Inc

Open

SectorHealthcare

23.38 1.87

Overview

Share price change

24h

Current

Min

22.9

Max

23.51

Key metrics

By Trading Economics

Income

-20M

-60M

Sales

-29M

60M

EPS

-0.64

Profit margin

-100.432

Employees

891

EBITDA

-32M

-51M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+40.03% upside

Dividends

By Dow Jones

Next Earnings

30 Jul 2025

Market Stats

By TradingEconomics

Market Cap

193M

1.8B

Previous open

21.51

Previous close

23.38

News Sentiment

By Acuity

37%

63%

124 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Schrodinger Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Nov 2024, 11:55 UTC

Top News

Schrödinger's Stock Soars 9% As It Enters Collaboration Pact With Novartis For Up To About $2.5 Billion In Payments -- MarketWatch

Peer Comparison

Price change

Schrodinger Inc Forecast

Price Target

By TipRanks

40.03% upside

12 Months Forecast

Average 32.71 USD  40.03%

High 45 USD

Low 26 USD

Based on 7 Wall Street analysts offering 12 month price targets forSchrodinger Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

23.27 / 26.13Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Very Strong Bullish Evidence

Sentiment

By Acuity

124 / 382 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.